Sanofi-aventis Announces the Creation of the "Sanofi Espoir" Corporate Foundation

Sanofi-aventisSanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the creation of the Sanofi Espoir Corporate Foundation, dedicated to implementing health and solidarity programs worldwide.

For more than 20 years, the commitment of the sanofi-aventis Group and its employees has been exemplified in wide-ranging community actions that aim to help and provide emergency humanitarian aid, enable better access to healthcare and combat chronic illness in developing countries. Constructed with the support and competencies of partners involved in the communities, these programs are part of a long-term development approach, with the objective of providing long-term support for the most vulnerable populations.

Aiming to capitalize on existing initiatives and develop new programs, the sanofi-aventis Group decided to create this Corporate Foundation, Sanofi Espoir, which will be chaired by Jean-François Dehecq. Hence, sanofi-aventis wants, through innovative measures, to pursue its goal of helping provide healthcare access to those patients who need it most.

"We are very pleased that Jean-François Dehecq will chair the Sanofi Espoir Foundation as it will continues to support the company's values and will allow us to put into practice important measures focusing on health issues in our civilization today," declared Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. "Health and Solidarity correspond to massive needs in terms of prevention, access and education. The Sanofi Espoir Corporate Foundation will find its strength in the engagement of all our employees."

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...